Kolling Institute Research award to Dr Chris Weir.

Dr Chris Weir’s work developing a cancer vaccine was recognised by the inaugural Kolling Institute Translational Award for the discovery with the greatest potential for incorporation into clinical use.

Dr Weir has developed a procedure for preparing autologous (self) vaccines from a tumour sample. In the laboratory, remission rates of 60% or extended survival were observed following challenge with brain cancer. Similar response rates with no side effects were seen in a trial in dogs treated with autologous vaccines to a variety of cancers.

With the increasing understanding of the importance of the immune system in fighting cancer, immunotherapy is now considered to be among the most promising approaches to modern cancer treatment.

The vaccine reintroduces tumour proteins back into a patient to induce immunity specifically against the tumour cells while leaving non‐cancerous cells unharmed.